Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity. A subgroup analysis of a large multi-centre, prospective, internet-based study

Journal of Crohn's and Colitis

Volumn 5, Issue 3, 2011, Pages 203-210

  Blumenstein, I ^a   Herrmann, E ^b   Filmann, N ^b   Zosel, C ^a   Tacke, W ^c   Bock, H ^c   Dignass A ^d   Hartmann, F ^e   Zeuzem, S ^a   Stein, J ^e   Schroder O ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Quality Management Group of Gastroenterologists in Hesse   (Germany)

^d AGAPLESION MARKUS KRANKENHAUS   (Germany)

^e St Marien Hospital   (Germany)

Author keywords

Disease duration; Gender; Immunosuppressive medication; Treatment differences

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE DURATION; ENTERITIS; FEMALE; GERMANY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SEX DIFFERENCE;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BUDESONIDE; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; CYCLOSPORINE; FEMALE; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MESALAMINE; METHOTREXATE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TACROLIMUS;

EID: 79955947158     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.12.012     Document Type: Article

References (41)

1. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004, 6:1504-1517.
2. Loftus E.V., Schoenfeld P., Sandborn W.J. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002, 1:51-60.
3. Shivananda S., Lennard-Jones J., Logan R., Fear N., Price A., Carpenter L., et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut 1996, 5:690-697.
4. Molinié F., Gower-Rousseau C., Yzet T., Merle V., Grandbastien B., Marti R., et al. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut 2004, 6:843-848.
5. Bernstein C.N., Blanchard J.F., Rawsthorne P., Wajda A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999, 10:916-924.
6. Ott C., Obermeier F., Thieler S., Kemptner D., Bauer A., Schölmerich J., et al. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. Eur J Gastroenterol Hepatol 2008, 9:917-923.
7. Moum B., Vatn M.H., Ekbom A., Aadland E., Fausa O., Lygren I., et al. Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) study group of gastroenterologists. Scand J Gastroenterol 1996, 4:362-366.
8. Caso V., Paciaroni M., Agnelli G., Corea F., Ageno W., Alberti A., et al. Gender differences in patients with acute ischemic stroke. Womens Health (Lond Engl) 2010, 1:51-57.
9. Shaw L.J., Shaw R.E., Merz C.N., Brindis R.G., Klein L.W., Nallamothu B., et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 2008, 14:1787-1801.
10. Oliver J.E., Silman A.J. Why are women predisposed to autoimmune rheumatic diseases?. Arthritis Res Ther 2009, 5:252.
11. Szalat A., Raz I. Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diab Obes Metab 2008, 12:1135-1156.
12. Harichand-Herdt S., Ramalingam S.S. Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Semin Oncol 2009, 6:572-580.
13. Allison J., Herrinton L.J., Liu L., Yu J., Lowder J. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol 2008, 9:999-1003.
14. Wagtmans M.J., Verspaget H.W., Lamers C.B., van Hogezand R.A. Gender-related differences in the clinical course of Crohn's disease. Am J Gastroenterol 2001, 5:1541-1546.
15. Söderlund S., Granath F., Broström O., Karlén P., Löfberg R., Ekbom A., et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010, 5:1697-1703.
16. Blumenstein I., Bock H., Weber C., Rambow A., Tacke W., Kihn R., et al. Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study. Inflamm Bowel Dis 2008, 1:53-60.
17. Blumenstein I., Bock H., Zosel C., Dignass A.U., Hartmann F., Zeuzem S., et al. Are there gender-related differences in the therapeutic management of patients suffering from inflammatory bowel disease? Subgroup analysis of a prospective multicentre online-based trial. Z Gastroenterol Oct 2009, 47(10):1045-1051. Epub 2009 Oct 6.
18. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 2-6. discussion 16-9.
19. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 4947:1041-1048.
20. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 8167:514.
21. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 6666:82-86.
22. Aldhous M.C., Drummond H.E., Anderson N., Baneshi M.R., Smith L.A., Arnott I.D., et al. Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol 2007, 3:577-588.
23. Johnson G.J., Cosnes J., Mansfield J.C. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005, 8:921-931.
24. Greenstein A.J., Sachar D.B., Panday A.K., Dikman S.H., Meyers S., Heimann T., et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992, 5:261-270.
25. Loftus E.V., Harewood G.C., Loftus C.G., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 1:91-96.
26. Hawthorne A.B., Rubin G., Ghosh S. Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008, 12:1157-1166.
27. Jackson C.A., Clatworthy J., Robinson A., Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010, 3:525-539.
28. Mantzaris G.J., Roussos A., Kalantzis C., Koilakou S., Raptis N., Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?. Inflamm Bowel Dis 2007, 4:446-450.
29. Willis F.R., Findlay C.A., Gorrie M.J., Watson M.A., Wilkinson A.G., Beattie T.J. Children of renal transplant recipient mothers. Children of renal transplant recipient mothers. J Paediatr Child Health 2000, 3:230-235.
30. Roubenoff R., Hoyt J., Petri M., Hochberg M.C., Hellmann D.B. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 1988, 2:88-110.
31. Bermas B.L., Hill J.A. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995, 12:1722-1732.
32. Ediger J.P., Walker J.R., Graff L., Lix L., Clara I., Rawsthorne P., et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007, 7:1417-1426.
33. Baars J.E., Zelinkova Z., Mensink P.B., Markus T., Looman C.W., Kuipers E.J., et al. High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study. Aliment Pharmacol Ther 2009, 8:864-872.
34. Bokemeyer B., Teml A., Roggel C., Hartmann P., Fischer C., Schaeffeler E., et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007, 2:217-225.
35. Dignass A.U., Hartmann F., Sturm A., Stein J. Management of inflammatory bowel diseases during pregnancy. Dig Dis 2009, 3:341-346.
36. Francella A., Dyan A., Bodian C., Rubin P., Chapman M., Present D.H. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003, 1:9-17.
37. Penn I., Makowski E.L., Harris P. Parenthood following renal transplantation. Kidney Int 1980, 2:221-233.
38. Rajapakse R.O., Korelitz B.I., Zlatanic J., Baiocco P.J., Gleim G.W. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000 Mar, 95(3):684-688.
39. Caprilli R., Gassull M.A., Escher J.C., Moser G., Munkholm P., Forbes A., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006, i36-i58.
40. Zelinkova Z., Mensink P.B., Dees J., Kuipers E.J., van der Woude C.J. Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases. Scand J Gastroenterol 2010, 1:46-50.
41. Heetun Z.S., Byrnes C., Neary P., O'Morain C. Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther 2007, 4:513-533.